Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism

被引：0
|
作者：
Hui-Yan Shi
Jin Yan
Wen-Hui Zhu
Guo-Ping Yang
Zhi-Rong Tan
Wei-Hua Wu
Gan Zhou
Xiao-Ping Chen
Dong-Sheng Ouyang
机构：
[1] Central South University,Pharmacogenetics Research Institute, Institute of Clinical Pharmacology
[2] Central South University,Third Xiangya Hospital
[3] Central South University,Department of Pharmacology, School of Pharmaceutical Science
来源：
European Journal of Clinical Pharmacology | 2010年 / 66卷
关键词：
Voriconazole; Erythromycin; CYP2C19; Genetic polymorphism; Chinese;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1131 / 1136
页数：5
相关论文
共 50 条
  • [41] A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism
    Hunfeld, N. G.
    Touw, D. J.
    Mathot, R. A.
    van Schaik, R. H.
    Kuipers, E. J.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2012, 35 (07) : 810 - 818
  • [42] A comparison of the acid-inhibitory effects of esomeprazole and pantoprazole in relation to pharmacokinetics and CYP2C19 polymorphism
    Hunfeld, N. G.
    Touw, D. J.
    Mathot, R. A.
    Mulder, P. G. H.
    van Schaik, R. H.
    Kuipers, E. J.
    Kooiman, J. C.
    Geus, W. P.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2009, 31 (01) : 150 - 159
  • [43] Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects
    Zhang, Dan
    Wang, Xiaolin
    Yang, Man
    Wang, Guocai
    Liu, Huichen
    XENOBIOTICA, 2011, 41 (06) : 511 - 517
  • [44] The effect of CYP2C19 polymorphism on the pharmacokinetics and acid-inhibitory effects of oral lansoprazole and omeprazole
    Bekkers, CHJ
    Touw, DJ
    Lamers, CBHW
    Geus, WP
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (05) : 553 - 553
  • [45] CYP2C19 gene polymorphism in Ningxia
    Zhen Yang
    Yunqian Xie
    Daya Zhang
    Yan Zou
    Ximei Li
    Runxiang Chen
    Xiaodong Zhang
    Shiju Chen
    Feihu Bai
    Pharmacological Reports, 2023, 75 : 705 - 714
  • [46] CYP2C19 gene polymorphism in Ningxia
    Yang, Zhen
    Xie, Yunqian
    Zhang, Daya
    Zou, Yan
    Li, Ximei
    Chen, Runxiang
    Zhang, Xiaodong
    Chen, Shiju
    Bai, Feihu
    PHARMACOLOGICAL REPORTS, 2023, 75 (03) : 705 - 714
  • [47] Effects of clarithromycin on lansoprazole pharmacokinetics between CYP2C19 genotypes
    Saito, M
    Yasui-Furukori, N
    Uno, T
    Takahata, T
    Sugawara, K
    Munakata, A
    Tateishi, T
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2005, 59 (03) : 302 - 309
  • [48] Effects of fluvoxamine on lansoprazole pharmacokinetics in relation to CYP2C19 genotypes
    Yasui-Furukori, N
    Saito, M
    Uno, T
    Takahata, T
    Sugawara, K
    Tateishi, T
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (11): : 1223 - 1229
  • [49] Influence of clarithromycin on the pharmacokinetics/pharmacodynamics of lansoprazole in relation to CYP2C19 polymorphism.
    Sohn, DR
    Kim, HK
    Kwon, JT
    Ishizaki, T
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 160 - 160
  • [50] CYP2C19*2 polymorphism and clopidogrel resistance
    Joob, Beuy
    Wiwanitkit, Viroj
    ARCHIVOS DE CARDIOLOGIA DE MEXICO, 2020, 90 (04): : 505 - 505
12345